Introduction
============

The development of next-generation sequencing (NGS) approaches has revolutionized human clinical research because of its ability to rapidly generate large volumes of sequencing data per run, with a concomitant decrease of sequencing costs ([@B72]). Unbiased ultra-deep sequencing of complex samples is now accessible, although bioinformatics analyses may still be long and tedious. This issue is particularly problematic in the field of infectious disease diagnostic, where the rapid identification and functional characterization of a particular pathogen is critical for the clinical management of infected patients. So far, polymerase chain reaction (PCR) has been the gold standard method for the clinical diagnosis of infectious diseases ([@B29]). This approach, which is based on the amplification of a generally short and conserved genomic region, can provide information on the presence/absence and abundance of a targeted microbial pathogen. PCR has numerous advantages, such as low cost, rapid processing and results acquisition, automation, sensitivity and specificity. However, and precisely because of its high specificity, PCR may not detect microorganisms whose sequences are too divergent from those targeted by the primers and probes designed. In addition, PCR will provide only partial information on the genetic diversity, genotype, functional potential, nutritional requirements as well as virulence or antibiotic-resistance. Such information, that could only be retrieved from whole genome sequencing (WGS), usually requires culture of the pathogen, which can be unsuccessful in the majority of cases (and particularly for viruses and other intracellular organisms which need host cells), can take several weeks for fastidious microorganisms or can be prevented by early administration of antimicrobial drugs. The power of NGS might thus be of particular interest in that cases for reconstructing full genomes of pathogens directly from nucleic acids extracted from clinical samples. However, due to the low pathogen/nucleic acid ratio in these complex biological samples, NGS may fail to detect/reconstruct genomes from pathogens present in low copy numbers in the sample. To overcome these limitations, capture methods, such as hybridization capture followed by NGS sequencing (also called hybrid-capture sequencing or target-enrichment sequencing) applied directly on human clinical samples have been developed ([@B50]). These approaches allow retrieving large genomic fragments to complete genomes with high sequencing coverage, which facilitate downstream investigations, such as phylogenetics, evolution, epidemiology, and drug resistance. In this review, we will briefly describe the different principles of hybridization capture coupled with NGS, its early developments on human genetic studies and applications in the recent years to the study of present and past human infectious diseases ([@B35]) directly from biological samples.

Overview of the Experimental Procedure and Applications
=======================================================

Next-generation sequencing hybridization-based capture is an approach directly applied after nucleic acid extraction and library preparation (Figure [1](#F1){ref-type="fig"}). Fragmented shotgun libraries are denatured by heating and subjected to hybridization with DNA or RNA single-stranded oligonucleotides (called also 'probes' or 'baits') specific to the region of interest ([@B44]). RNA baits are preferable, because RNA:DNA duplexes are better in term of hybridization efficiency and stability, compared to DNA:DNA hybrids ([@B47]). Non-specific unbound molecules are washed away, and the enriched DNA is eluted for NGS ([@B44]). The hybridization between DNA libraries and baits can be carried out in solution or on a solid support. In "solid-phase," DNA probes are bound to a solid support, such as a glass microarray slide ([@B1]; [@B60]), where in "solution-capture," free DNA or RNA probes are biotinylated allowing them to isolate the targeted fragment-probe heteroduplexes using magnetic streptavidin beads ([@B36]). So far, there is no standardize protocol for target enrichment processes and several adjustments can be made on library fragment size, sample fragmentation, cleanup procedures, number of PCR amplification cycles, and/or the hybridization duration. Detailed protocols are described in the work of [@B50] along with values on specificity, sensitivity and reproducibility of each tested procedure. The ultimate step of NGS hybridization-based capture is the sequencing of the enriched nucleic acids and bioinformatic analyses of the reads. The last process usually includes steps of trimming (for adapter sequences, low quality and duplicate reads), mapping of the remaining reads on reference genomes for pathogen detection and identification, and/or assembly into contigs for genome reconstruction (Figure [1](#F1){ref-type="fig"}). The information provided by the genome can further be explored to investigate the genetic diversity (strain genotyping, variant detection), epidemiology, evolutionary history, transmission networks, and/or antimicrobial resistance of the target pathogen(s).
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Early Developments of Hybrid-Capture Strategies: Human Genetic Studies on Modern and Ancient Samples
====================================================================================================

Target-enrichment strategy using hybrid capture was originally developed for human genomic studies for which it was used to capture and sequence the entire human exome. This genomic technique, also called exome sequencing (or whole exome sequencing) was first applied by using an array-based hybrid capture method in 2007 ([@B40]). In this study, the authors developed six customized NimbleGen arrays to capture about 180,000 coding exons with overlapping 60--90-nt probes allowing an average enrichment of exon DNA sequences of 323 folds. Whole exome sequencing using capture arrays has proven its usefulness in identifying rare variants and mutations causing disease ([@B16]; [@B59]). The limitations of this technique include the need to design an array and a relatively large amount of DNA. To overcome some of the weaknesses of the previous method, [@B36] have developed an in-solution hybrid capture method for human whole exome sequencing. To do so, biotinylated RNA baits of 170 bases in length were constructed, targeting 5,565 human protein-coding exons. In this study, authors have demonstrated the possibility to perform hybrid selection in solution. Following this, many targeted human exome in-solution enrichment methods for NGS have been developed, including those commercialized by Illumina ^[1](#fn01){ref-type="fn"}^ and Agilent Genomics ^[2](#fn02){ref-type="fn"}^ ([@B14],[@B15]). In-solution capture for exome sequencing turned out to be an effective approach applied to discover the causal mutation of rare Mendelian disorders ([@B71]; [@B53]; [@B58]; [@B65]), of complex disorders ([@B63]; [@B39]; [@B38]; [@B61]), mitochondrial disorders ([@B11]; [@B34]) and more recently of the screening of potential genetic mutation of patients suffering from cancer ([@B73]; [@B25]; [@B80]; [@B66]; [@B81]; [@B19]; [@B67]).

The power of hybridization capture has been also successfully used to study human ancient DNA (aDNA) preserved in ancient human remains. Indeed, in ancient human samples, DNA is highly fragmented (thus a shotgun fragmentation step is usually not required) and dominated by a large contamination of environmental and bacterial DNA, which poses a limitation in shotgun aDNA sequencing experiment ([@B43]). Another characteristic of aDNA is cytosine deamination on the ends of DNA fragments. Library construction can be done directly on the double stranded DNAs (dsDNAs) or single stranded DNAs (ssDNAs) and may include cytosine deamination removal by the use of a damage treatment step with uracil DNA glycosylase and/or endonuclease VIII ([@B7]). The first genetic marker analyzed in human paleogenetic studies was mitochondrial DNA (mtDNA) because of its higher copy number in the cell than nuclear DNA. Probe hybridization assays used biotinylated DNA or RNA probes targeting the two hypervariable segments of the mtDNA control region (CR) ([@B6]; [@B45]; [@B52]; [@B30]; [@B42]; [@B76]; [@B28]; [@B49]). Another uniparental marker, the Y-chromosome DNA (Y-DNA), was also used to study aDNA. As each cell possesses only one copy of the Y chromosome, the hybridization capture was carried out to enrich specific genomic regions of the Y chromosome both on solid support ([@B33]) and in solution ([@B20]). However, targeting mitochondrial DNA or Y chromosome involves discarding a large proportion of potentially informative sequences present in autosomal DNA. For this reason, [@B12] reported a new capture-based method, called whole-genome in-solution capture (WISC), using modern DNA as bait covering the entire human genome. This method was applied to 12 ancient human DNA libraries and showed an enrichment of 6 to 159 folds of the sequence mapping to the human genome with enrichments of 2 to 13 folds for unique fragments ([@B12]). As for modern human genetic studies, commercial kits targeting mitochondrial DNA, custom loci, or entire nuclear genomes, such as those developed by Arbor Bioscience (myBaits^®[3](#fn03){ref-type="fn"}^) are now employed in the genetic sequencing of ancient DNA ([@B31]; [@B48]).

Applications of Target-Enrichment Sequencing to Human Infectious Diseases
=========================================================================

Parasites and Fungi
-------------------

The first application of hybrid selection method for infectious diseases was in the field of human parasitology research([@B55]; Table [1](#T1){ref-type="table"}). To overcome the low proportion of *Plasmodium falciparum* sequences relative to that of their human host, authors have proposed to adapt in-solution NGS hybrid capture method to enrich this pathogen. This protocol has been tested in both mock mixtures composed of 99% human DNA and 1% *Plasmodium* but also in *P. falciparum* clinical samples. For this purpose, synthetic 140 bp oligos labeled with biotin were designed to capture exonic regions of the *P. falciparum* genome, whereas 250 bp oligos were constructed to target the entire genome. Processed and unprocessed samples were then sequenced with an Illumina technology. In the mockmetagenome, sequencing of the hybrid-selected samples yielded between 37 to 44-fold enrichment of the parasite DNA. In the human clinical sample, Illumina sequencing showed that at least 5.9% of reads mapped to *Plasmodium*, but no data was provided regarding the percentage of *Plasmodium* reads obtained without hybrid capture ([@B55]). However, this first study highlighted the good performance of NGS hybrid capture to sequence parasite genome from human clinical samples. In 2012, other studies confirmed the good performance of in-solution hybrid capture to enrich *P. falciparum* ([@B74]) sequences and *P. vivax* ([@B8]).

###### 

Example of studies that used target-enrichment sequencing for parasitic, fungal, bacterial, or viral diseases in modern and ancient samples.

  Targeted organism                                                                                                    Probes design                                                    Infectious disease                                    Sample tested                                            Methods       Nucleic acids        Sequencing                           Reference
  -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------- -------------------------------------------------------- ------------- -------------------- ------------------------------------ -----------
  **Parasitic and fungal disease**                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                                               
  *Plasmodium falciparum 3D7*                                                                                          Whole genome                                                     Malaria                                               Mock sample whole blood                                  In-solution   DNA                  Illumina GAIIx Illumina HiSeq        [@B55]
  *P. falciparum 3D7*                                                                                                  Whole genome                                                     Malaria                                               Mock sample Whole blood                                  In-solution   DNA                  Illumina GAIIx                       [@B74]
  *Plasmodium vivax*                                                                                                   Whole genome                                                     Malaria                                               Whole blood                                              In-solution   DNA                  Illumina HiSeq                       [@B8]
  *Candida albicans*                                                                                                   6094 ORFS                                                        Systemic candidiasis                                  Animal model of infection                                In-solution   RNA (cDNA)           Illumina HiSeq                       [@B2]
                                                                                                                                                                                                                                                                                                                                                                               
  **Bacterial disease**                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                               
  *Chlamydia trachomatis*                                                                                              74 References whole genome                                       Trachoma                                              Vaginal swabs Urine                                      In-solution   DNA                  Illumina MiSeq                       [@B17]
  *Mycobacterium tuberculosis H37Rv*                                                                                   Whole genome                                                     Multidrug-resistant tuberculosis                      Sputum                                                   In-solution   DNA                  Illumina MiSeq                       [@B9]
  *Neisseria meningitidis*                                                                                             77 Complete reference genome and 2898 drafts                     Invasive meningococcal disease                        CSF Whole blood                                          In-solution   DNA                  Illumina MiSeq                       [@B18]
                                                                                                                                                                                                                                                                                                                                                                               
  **Viral disease**                                                                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                               
  *Varicella-zoster virus Epstein--Barr virus Kaposi's Sarcoma-Associated Herpesvirus*                                 Whole genome                                                     Zoster-vaccine rash, wild-type zoster, encephalitis   Clinical and cultured samples                            In-solution   DNA                  Illumina GAIIx                       [@B22]
  *Merkel cell polyomavirus (MCPyV)*                                                                                   23 Overlapping PCR products that tiled across the MCPyV genome   Merkel cell carcinoma                                 Formalin-Fixed, Paraffin-Embedded Tissue                 In-solution   DNA                  Illumina GAIIx                       [@B27]
  *Human Herpesvirus 7 (HHV7)*                                                                                         Whole genome                                                     Exanthem subitum                                      Cellular culture                                         In-solution   DNA                  Illumina MiSeq                       [@B23]
  *Epstein--Barr Virus (EBV)*                                                                                          Whole genome                                                     Nasopharyngeal carcinoma (NPC)                        NPC tumor biopsy                                         In-solution   DNA                  Illumina MiSeq                       [@B46]
  *Zika virus (ZIKV)*                                                                                                  Whole genome                                                     ZIKV infection                                        Blood, urine, cerebrospinal fluid, and saliva            In-solution   RNA (cDNA)           Illumina HiSeq                       [@B56]
  *Lassa virus*                                                                                                        2 References complete genome                                     Hemorrhagic fevers                                    Plasma or serum                                          In-solution   RNA (cDNA)           Illumina HiSeq                       [@B54]
  *Varicella Zoster Virus (VZV)*                                                                                       Whole genome                                                     Vaccine-associated rashes                             Vesicular fluid                                          In-solution   DNA                  Illumina (GAIIx, HiSeq, and MiSeq)   [@B21]
  *ViroCap 337 DNA and RNA viral species infecting human and animals*                                                  1456 RefSeq + genome neighbor sequences (185,835 fasta total)    n.a.                                                  Panel of human samples                                   In-solution   DNA and RNA (cDNA)   Illumina HiSeq                       [@B79]
  *VirCapSeq-VERT 207 viral taxa infecting vertebrates*                                                                342,438 Coding sequences (1,993,200 oligonucleotide probes)      n.a.                                                  Mock samples Human clinical samples and animal samples   In-solution   DNA and RNA (cDNA)   Illumina HiSeq                       [@B5]
  *Norovirus*                                                                                                          662 References complete or partial genome                        Acute gastroenteritis                                 Stool suspensions                                        In-solution   RNA (cDNA)           Illumina MiSeq                       [@B10]
  *Hepatitis C Virus (HCV)*                                                                                            953 Reference complete genomes                                   HCV infections                                        Plasma Mock samples RNA transcripts                      In-solution   RNA (cDNA)           Illumina MiSeq                       [@B77]
  *Exogenous retroviruses* Immunodeficiency virus type-1 (HIV-1) and the human T-cell leukemia virus type-1 (HTLV-1)   Whole genome                                                     n.a.                                                  Infected cells                                           In-solution   DNA                  Illumina MiSeq                       [@B57]
  *Herpes simplex virus 1 and 2 (HSV-1/HSV-2)*                                                                         Whole genome                                                     Skin rash, herpetic lesions                           Swab of the lesion                                       In-solution   DNA                  Illumina MiSeq                       [@B37]
  *ViroFind 535 DNA and RNA viral species that are known to infect humans*                                             Whole genome                                                     Progressive multifocal leukoencephalopathy (PML)      ^:^Post mortem PML brain samples                         In-solution   DNA and RNA (cDNA)   Illumina MiSeq                       [@B13]
                                                                                                                                                                                                                                                                                                                                                                               
  **Infectious diseases in paleomicrobiology**                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                               
  *Yersinia pestis strain CO92*                                                                                        Whole genome or pCD1 and pMT1 plasmids                           Plague (Black Death) 1347--1351                       Teeth                                                    Microarray    DNA                  Illumina GAIIx                       [@B4]
  *Y. pestis strain CO92*                                                                                              Portion of the *Y. pestis* pPCP1 plasmid                         Plague (Black Death) 1347--1351                       Bones and Teeth                                          In-solution   DNA                  Illumina GAIIx                       [@B68]
  *Y. pestis strain CO92*                                                                                              Core genome, plasmids and 155 other genes                        Plague (Justinian) (6--8th centuries)                 Teeth                                                    In-solution   DNA                  Illumina HiSeq                       [@B78]
  *Mycobacterium tuberculosis*                                                                                         rpoB, gyrA, gyrB, katG, and mpt40 genes                          Tuberculosis (1000 year old)                          Skeletal samples                                         In-solution   DNA                  Illumina HiSeq                       [@B3]
  *Mycobacterium leprae*                                                                                               3 Genomic loci                                                   Leprosy (11th to 14th century)                        Bones and teeth                                          In-solution   DNA                  Illumina MiSeq and HiSeq             [@B70]
  *Variola virus*                                                                                                      Whole genome                                                     Smallpox (1643--1665)                                 Mummified tissues of a child                             In-solution   DNA                  Illumina HiSeq                       [@B26]
  *P. falciparum*                                                                                                      Mitochondrial genomes of *Plasmodium* spp.                       Malaria (1st--2nd century)                            Teeth                                                    In-solution   DNA                  Illumina HiSeq                       [@B51]
  *Treponema pallidum*                                                                                                 Whole genome                                                     Syphilis (1681 to 1861)                               Bones                                                    Microarray    DNA                  Illumina HiSeq                       [@B69]

n.a., not applicable.

Fungi are also a major cause of human diseases that can be particularly serious in immunocompromized patients or in patients hospitalized for serious diseases ([@B62]). For example, systemic infections with *Candida albicans* in immunocompromized patients result in mortality rates of about 50% ([@B62]). The prevention, diagnosis and therapy of fungi infections remain very difficult and comprehension of transcriptional regulation between fungal pathogens and host is an important step to identify potential novel targets for drug development ([@B62]). Again, the limitations of host and pathogen transcriptome analysis lie in the low proportion of fungal RNA present in the total extracted RNA. The use of specific enrichment procedures before RNASeq analysis has then been proposed as an alternative method to overcome the problem of low fungus/host RNA ratio. For this purpose, [@B2] have designed a set of 55,342 biotinylated 120 bp-RNA probes covering 6,094 *C. albicans* ORFs. cDNA libraries were established using SureSelect (Agilent) after extraction of RNA from mice kidney or *Galleria mellonella* larvae infected with *C. albicans*, and were subjected to capture with biotinylated probes before Illumina HiSeq sequencing. Results showed up to a 1670-fold enrichment of *C. albicans* reads in a given biological sample and a detection of more than 86% of its genes. Many genes that have been regulated in *in vivo* infection experiments have functions that have not yet been characterized and will require further research to understand their role during infection ([@B2]).

Bacteria
--------

In bacteriological research and diagnostic, targeted capture strategies prior to sequencing could be a powerful tool in the management and therapeutics of patients with infectious disease. Indeed, the rapid identification of antimicrobial resistance is essential for a rapid and effective treatment. Regarding *Mycobacterium tuberculosis*, current methods of screening for antimicrobial resistance, which are based on the culture of the organism from sputum samples before sequencing, can take up to several weeks. To overcome these limitations, Brown et al. have proposed to use oligonucleotide enrichment technology to capture *M. tuberculosis* genome sequences directly from positive smear sputum samples ([@B9]; Table [1](#T1){ref-type="table"}). Whole genome baits (120-mer RNA baits) were designed to span the entire positive strand of the *H37Rv M. tuberculosis* reference genome and synthesized by Agilent Technologies. The authors demonstrated the reliability of targeted sequencing to recover and sequence, in less than 96 h, nearly complete genomes directly from 81% (21/26) smear positive sputa but also its robustness to identify the genotype and resistance determinants of all samples that were previously tested positive samples. This study emphasizes the use of hybrid selection target enrichment that could allow personalized antimicrobial treatment in multidrug-resistant tuberculosis ([@B9]). Other studies have used biotinylated baits spanning entire genomes for high-resolution strain genotyping directly from clinical samples. Indeed, discrimination of *Chlamydia trachomatis* serovars from genital samples would facilitate the study of population structures and modes of transmission ([@B17]) while genomic data from uncultured *Neisseria meningitidis* not grown in the case of invasive meningococcal would allow increased surveillance of vaccine antigens and studies on possible vaccine deficiencies ([@B18]).

Viruses
-------

In viral research and diagnostic laboratories, viral WGS is also essential for the detection of drug resistance and the development of novel treatments and vaccines ([@B41]). In this domain, the first study that demonstrated the effectiveness of target capture technology for reconstructing full herpesvirus genomes from complex biological samples was proposed by [@B22] (Table [1](#T1){ref-type="table"}). In this study, 120-mer RNA baits generating a 2× coverage for Varicella-Zoster Virus (VZV), a 5× coverage for Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated Herpesvirus (KSHV), were synthetized and hybridized with DNA extracted from a range of clinical samples including blood, saliva, vesicle fluid, cerebrospinal fluid, and tumor cell lines. Full-length herpes virus genomes were reconstructed at high read depth for the 13 samples tested and generated further studies on the structure and diversity of the viral population ([@B22]). Following this study, the capture of whole genomic hybrids made it possible to study the genomic diversity of eight new complete EBV genomes isolated from biopsy specimens of primary nasopharyngeal carcinomas ([@B46]), 37 Zika virus genomes (ZIKV) samples out of 66 attempts ([@B56]), 453 complete genomes (with \>90% genome coverage and \>100-fold read depth) of different norovirus genotypes from 509 stool samples ([@B10]) and to achieve sufficient coverage for *de novo* genome assembly and detection of single nucleotide variants of Lassa virus (LASV) from ultra-low input samples ([@B54]). This approach has been also used to characterize other clinically relevant viruses, such as hepatitis C virus (HCV) ([@B77]), varicella zoster virus ([@B21]), human herpesvirus 7 (HHV-7) ([@B23], 7) and the herpes simplex virus 1 and 2 (HSV-1 and HSV-2) ([@B37]). Hybrid capture associated with shotgun sequencing could also be performed using a combination of several viral species used as baits. Indeed, [@B79] developed ViroCap, a panel of probes designed to enrich nucleic acid from 34 families of DNA and RNA viruses (190 viral genera and 337 species) that infect vertebrate hosts, except human endogenous retrovirus. These probes were tested both on a pool of 14 clinical samples, which tested positive for a viral infection, and on eight samples from young children with fever, also positive for one or more viruses. Libraries were sequenced before capture (pre-capture) and following capture using ViroCap (post-capture). Combining results from both experiments, 32 viruses were detected (11 additional in the post-captured samples), including diverse DNA and RNA viruses (with genomes ranging from 5--161 kb) with genomic coverage \>80% for 16 of the 32 genomes. Several complete genomes were reconstructed and belonged to Human bocavirus 1, Human parvovirus B19, human adenovirus B (type 3), human adenovirus C (type 1), KI polyomavirus, sapovirus, and human astrovirus 1. Finally, although ViroCap cannot detect viral sequences that are completely novel, its design, which includes neighbor genomes of reference sequences, allows variants with nucleotide sequence identity as low as 58% to be identified ([@B79]). The same year, VirCapSeq-VERT, a virome capture sequencing platform targeting 207 viral taxa infecting vertebrates was described ([@B5]). VirCapSeq-VERT allowed reduction of background human DNA and a 100 to 10,000 fold enrichment in viral reads when compared with other enrichment procedures such as treatment with nucleases or RiboZero rRNA depletion ([@B5]). In 2018, a similar approach called ViroFind was designed to target 535 DNA and RNA viruses, which are known to infect humans or cause zoonoses. This in-solution target enrichment was applied to the brain biopsy samples of five patients with progressive multifocal leukoencephalopathy (PML) ([@B13]). It allowed the description of highly complex Polyoma virus JC populations as well as the detection of large genetic divergence among variants, with some of these mutations conferring viral fitness advantages ([@B13]). Lastly, other applications of target-enrichment sequencing have been described, such as the study of viral genome integrations within the human genome. This approach was powerful and efficient to identify Merkel Cell Polyomavirus (MCPyV) insertion sites on DNA extracted from formalin-fixed and paraffin-embedded tissue from Merkel cell carcinoma ([@B27]). It also allowed to analyze retroviral genomes integrated within host genomic DNA in case of human T-cell leukemia virus type-1 (HTLV-1) and human immunodeficiency virus type-1 (HIV-1) infections ([@B57]).

Paleomicrobiology
-----------------

Paleomicrobiology is an emerging research field dedicated to the detection, identification and characterization of microorganisms (bacteria, viruses, and parasites) in ancient specimens. Elucidating past infectious diseases can lead to a better understanding of the temporal and geographical distributions of infected individuals, the introduction of microorganisms into human populations, the host-pathogen relationships but also the genetic evolution of the microorganisms ([@B24]). The main limitations of paleomicrobiological studies concern the degradation of ancient DNA (aDNA) and the risk of contamination by modern DNA ([@B64]). Target-enrichment prior to sequencing is therefore a particularly relevant tool in this context for genomes study. The first two studies using targeted enrichment in paleomicrobiology have investigated genetic changes and virulence factor of *Yersinia pestis*, the causal agent of the second plague pandemics (Black Death, 14--17th centuries) ([@B4]; [@B68]; Table [1](#T1){ref-type="table"}). To this end, an array-based enrichment using probe targeting either the full *Y. pestis* chromosome or *pestis*-specific virulence plasmids was applied directly after the DNA extraction from ancient bones ([@B68], 1) and/or teeth ([@B4]; [@B68]). Using targeted DNA capture approach combined with high-throughput sequencing, the authors reconstructed 99% of the pPCP1 plasmid sequence ([@B68]) and a draft genome of *Y. pestis* ([@B4]) with the molecular damages typically associated with aDNA. Comparisons with modern genomes did not identify any significant genetic variation that could explain the differences between the ancient and modern forms of the disease ([@B68]). More recently, three other draft genomes of *Y. pestis* have been recovered from individuals who died during the first plague pandemics (the Plague of Justinian, 6--8th centuries) in two different rural sites in southern Germany ([@B78]; [@B32]). Genetic characterization showed that these 3 drafts derived from a single Justinianic strain which is unique and harbors novel substitutions and structural polymorphism ([@B78]; [@B32]). Finally, target enrichment sequencing also allowed the reconstruction of new *Y. pestis* strains from Bronze Age individuals (∼3,800 BP) ([@B75]) providing further datas into the early stages of *Y. pestis* genome evolution including on genomic characteristics supporting flea-borne transmission in rodents or humans ([@B75]). Finally, target-enrichment sequencing approaches in the paleomicrobiological research field have not been exclusively applied to the study of ancient plague pandemics, but have also allowed genomic investigation of ancient *Mycobacterium tuberculosis* ([@B3]), *M. leprae* ([@B70]), *Variola virus* ([@B26]), *P. falciparum* ([@B51]), and *Treponema pallidum* ([@B69]) in human remains.

Conclusion
==========

Target-enrichment sequencing is an efficient approach that allows large fragments and even entire sequences of the genome of targeted microorganisms to be reconstructed directly from modern and ancient complex biological samples containing a low pathogen/host nucleic acid ratio. The information provided by the genome can be used to explore the genetic diversity, epidemiology, evolutionary traits, transmission networks, host-pathogen interactions or antimicrobial resistance of the target pathogen or its variants. The main current limitations of democratizing target-enrichment sequencing in clinical diagnostic laboratories are its elevated cost, the high expertise required for library preparation and the necessary time to generate biotinylated probes from reference genomes, which hampers a rapid response to an emerging pathogen. Above all, it is not suitable for the detection and characterization of completely novel microorganisms, including viruses whose emergence may represent one of the main threats to human health in the near future.
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